Full Year 2024 Conference Call & Audio Webcast BioVersys will host a conference call and webcast at 2:00 PM CET to discuss the financial results, provide an update on the company’s performance, ...

The first phase 3 trials are due to start in the first half of next year, using devices manufactured at GSK’s facility in Evreux, France. “If successful, this could lead to regulatory ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

The product -- called Blujepa -- was approved for the treatment of uncomplicated urinary tract infections in adult women and ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab).

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

March 26, 2025, 7am CET BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

According to Research by SNS Insider, the global Teeth Whitening Market growth is fueled by rising aesthetic consciousness and advancements in whitening technology.Pune, March 26, 2025 (GLOBE NEWSWIRE ...